Podium presentation showcases the clinical application of Precise™ MRDSALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

About the Study The study analyzed a dataset generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claim ...

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

No one should look back at the last week and forget that millions of people, perhaps more, were and will be directly worse off thanks to Donald Trump. It may be some consolation that Trump himself ...

Analyst Price Forecast Suggests 107.09% Upside As of April 1, 2025, the average one-year price target for Myriad Genetics is $17.50/share. The forecasts range from a low of $8.08 to a high of $30.45.

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the ...

A new genomic study has uncovered long-lost genetic diversity in mammoth lineages spanning over a million years, providing new insights into the evolutionary history of these animals. A new ...

The outer reef at Moorea in a coral dominated state. In dynamic ecosystems, and especially in the nutrient-limited environments where coral reefs grow, not much will go to waste. Microbes dominate ...